Summary:
A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder.
Qualified Participants Must:
• Be 18 to 75 years of age
•
Be diagnosed with MDD (Major Depressive Disorder)
•
Currently be depressed, with the current episode lasting between 3 months and 2 years
•
Not have any history of drug or alcohol abuse or dependence
•
Be physically healthy
Qualified Participants May Receive:
All study-related evaluations, medication, and doctors' visits at no cost; compensation for those who qualify.